FLT4 anticorps (AA 1112-1329)

N° du produit ABIN7175388

L’anticorps Lapin Polyclonal anti-FLT4 a été validé pour IHC, ELISA et IF. Il convient pour détecter FLT4 dans des échantillons de Humain.

Aperçu rapide pour FLT4 anticorps (AA 1112-1329) (ABIN7175388)

Antigène: FLT4 (Fms-Related Tyrosine Kinase 4 (FLT4))

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp FLT4 est non-conjugé

Application: Immunohistochemistry (IHC), ELISA, Immunofluorescence (IF)

Détail du produit anti-FLT4 anticorps

Épitope: AA 1112-1329

Fonction: FLT4 Antibody

Purification: Protein G purified

Pureté: >95 %

Immunogène: Recombinant Human Vascular endothelial growth factor receptor 3 protein (1112-1329AA)

Isotype: IgG

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, PH 7.4

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C,-80 °C

Stockage commentaire: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Détails sur FLT4

Antigène: FLT4 (Fms-Related Tyrosine Kinase 4 (FLT4))

Autre désignation: FLT4

Sujet:

Background: Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFC and VEGFD, and plays an essential role in adult lymphangiogenesis and in the development of the vascular network and the cardiovascular system during embryonic development. Promotes proliferation, survival and migration of endothelial cells, and regulates angiogenic sprouting. Signaling by activated FLT4 leads to enhanced production of VEGFC, and to a lesser degree VEGFA, thereby creating a positive feedback loop that enhances FLT4 signaling. Modulates KDR signaling by forming heterodimers. The secreted isoform 3 may function as a decoy receptor for VEGFC and/or VEGFD and play an important role as a negative regulator of VEGFC-mediated lymphangiogenesis and angiogenesis. Binding of vascular growth factors to isoform 1 or isoform 2 leads to the activation of several signaling cascades, isoform 2 seems to be less efficient in signal transduction, because it has a truncated C-terminus and therefore lacks several phosphorylation sites. Mediates activation of the MAPK1/ERK2, MAPK3/ERK1 signaling pathway, of MAPK8 and the JUN signaling pathway, and of the AKT1 signaling pathway. Phosphorylates SHC1. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase. Promotes phosphorylation of MAPK8 at \'Thr-183\' and \'Tyr-185\', and of AKT1 at \'Ser-473\'.

Aliases: EC 2.7.10.1 antibody, flt 4 antibody, FLT-4 antibody, FLT4 antibody, FLT41 antibody, Fms related tyrosine kinase 4 antibody, Fms-like tyrosine kinase 4 antibody, LMPH1A antibody, PCL antibody, Soluble VEGFR3 variant 1 antibody, Soluble VEGFR3 variant 2 antibody, Soluble VEGFR3 variant 3 antibody, Tyrosine protein kinase receptor FLT4 antibody, Tyrosine-protein kinase receptor FLT4 antibody, Vascular endothelial growth factor receptor 3 antibody, Vascular endothelial growth factor receptor 3 precursor antibody, VEGF R3 antibody, VEGFR 3 antibody, VEGFR-3 antibody, VEGFR3 antibody, VGFR3_HUMAN antibody

UniProt: P35916

Pathways: Signalisation RTK, Signaling Events mediated by VEGFR1 and VEGFR2, VEGF Signaling